Session » Plenary Session II: Discovery 2012

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 1593

The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis

Abstract Number: 1594

Clinical and Radiological Outcomes After One Year of Remission Steered Combination Treatment in Patients with Early Rheumatoid and Undifferentiated Arthritis

Abstract Number: 1595

Genome-Wide Association Study to High -Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling

Abstract Number: 1596

Strontium Ranelate in Knee Osteoarthritis Trial (SEKOIA): A Structural and Symptomatic Efficacy

Abstract Number: 1597

Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase 3 Trial

Abstract Number: 1598

Clinical and Serologic Predictors of Response in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – the RIM Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.